Aberrant Cytokine Receptor Signaling in Hematological Cancers and Proliferative Disorders
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 20 November 2025 | Viewed by 477
Special Issue Editor
Interests: cell–cell signaling; cytokines; JAK–STAT pathway; hematology; immunology; developmental biology; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cytokine receptor signaling represents a paradigm for cell-to-cell communication, which plays a particularly pivotal role in facilitating the generation, maintenance, and function of blood and immune cells. Perhaps unsurprisingly, mutations and other aberrations impacting cytokine receptor signaling have been identified as the key causative agents for a diverse range of malignancies affecting the blood and immune cells, including proliferative disorders, leukemias and lymphomas.
This Special Issue will focus on these pathogenic aberrations in cytokine receptor signaling, highlighting the molecular underpinnings, their modes of action and their specific clinical presentations. It will detail relevant cellular and animal studies that model these disorders, as well as the pre-clinical and clinical studies that aim to investigate potential therapeutic strategies to ameliorate the effects of aberrant cytokine receptor signaling.
Prof. Dr. Alister C. Ward
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytokine receptor
- signaling
- leukemia
- lymphoma
- myeloproliferative neoplasm
- hematology
- oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
